Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.745 USD | -2.10% | -9.89% | +28.07% |
07:05pm | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.07% | 29.89M | |
+64.81% | 62.59B | |
-1.31% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.48% | 26.21B | |
-21.66% | 19.09B | |
+4.85% | 13.08B | |
+25.57% | 12.26B | |
+28.14% | 12.05B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating